Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

ung and ovarian cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The primary objective of the trial was to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN when administered in combination with gemcitabine. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

Gemzar(R) is indicated for NSCLC, breast, pancreatic and ovarian cancer. For more information about Gemzar(R), please visit www.gemzar.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. and U.S. combination REOLYSIN/gemcitabine clinical trials and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue researc
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... November 24, 2014 2014 Deep ... Industry is a professional and in-depth research report ... Dihydrazide information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/22/2014)... and London (PRWEB) November 21, 2014 Two ... will explore what comes next for ALS research and how ... , After the Ice Bucket Challenge: Where Does the ... Date: Tuesday, 2 December 2014, Time: 1:30pm ET, ... , Join expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor ...
(Date:11/22/2014)... IL (PRWEB) November 21, 2014 On ... competitors at the 2014 Emerging Medical Technologies Summit in ... Innovator Awards. Widely regarded among Silicon Valley investors ... medical device innovation, the win also positions Briteseed ... MedTech Innovator competition in 2015 and compete with other ...
(Date:11/21/2014)... -- , Todd Martensen se ... Mariano Rodríguez es elegid vicepresidente senior de desarrollo empresarial y ... marcha para comenzar de forma rápida la comercialización de su ... en Europa   , KLOX Technologies ... siguientes nombramientos: Todd Martensen ha sido ...
Breaking Biology Technology:Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5
... - Human neural stem cells, exposed in a lab dish ... rates, suggesting that the hormone may play a role in ... study published this week in the online editions of the ... new work, conducted by a team of scientists at the ...
... Lands End, Inc., , Wisconsin-based online clothing retailer, introduced Thursday ... effort to take the guesswork out of online shopping. , ... men and women find clothes that fit correctly by modeling ... more life-like model that closely resembles the customer. , ,Our ...
... and Chemicon International, Inc. announced today ... and apply Madison-based Promegas DNA-directed, RNA interference (ddRNAi) ... division of Serologicals Corporation, will have the right ... ddRNAi-based products and reagents for life science research. ...
Cached Biology Technology:DHEA Boosts Growth Rate of Human Neural Stem Cells 2DHEA Boosts Growth Rate of Human Neural Stem Cells 3
(Date:11/18/2014)... Nov. 17, 2014 The Parenteral Drug Association (PDA) ... agencies will speak and at least seven more will participate ... the Omni Shoreham Hotel in Washington D.C. ... to have significant support from the regulatory agencies in ... in our effort to help advance the use ...
(Date:11/10/2014)... on U.S. store shelves in early 2010, and people ... small packets can be tossed into a washing machine ... powder. The convenience, though, has come with risks for ... Nationwide Children,s Hospital found that from 2012 through 2013, ... younger than 6 years of age swallowing, inhaling, or ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3
... 15, 2013  Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com ... and patented systems to various medical and retail related ... corporate governance and transparency in the mushrooming legal marijuana industry and ... the status of past, present, and future projects. ...
... 15, 2013   Evolution Marketing Research , a leading supplier ... three new industry professionals. Ian Fureman ... as Associate Methodologist; and Shannon Sesa ... Fureman brings to Evolution more than 14 years of ...
... 14, 2013) Through a collaborative genome-wide study on ... are associated with heart rate. Since heart rate ... provide a better understanding of genetic regulation of heart ... for new drugs to treat cardiovascular disease. The ...
Cached Biology News:Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 2Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 3Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 4Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 5Evolution Marketing Research Grows its Practice with Addition of Three Key Industry Professionals 2Evolution Marketing Research Grows its Practice with Addition of Three Key Industry Professionals 3Mount Sinai study identifies new gene variations associated with heart rate 2
... two-position, three-way universal digital valve, just 8 mm ... its functional features in a single glass-reinforced, PBT ... only 8mm in width. , Meets a range ... 100 psi. , Satisfies a 0.016 sccm leakage ...
... Series offers high performance miniature stepper motors ... and 34 frame sizes. These space-efficient 1.8 ... science applications, including medical instrumentation, medical devices, ... systems., Meets a wide range of ...
... been designed to save time and provide ... in eliminating the recycling and resterilizing necessary ... packaged, RNase/DNase free, non-pyrogenic and antistatic. Linkage: ... number, created to easily match Cornings product ...
... PBL's bioassays for interferons are cytopathic effect ... antiviral assays. The neutralization assay measures ... activity of the cytokine. Sample types include; ... In these assays, one unit is ...
Biology Products: